PURPOSE: Chemotherapy in AL (primary or light chain) amyloidosis is associated with improved survival, but its effect on renal outcome has not been examined systematically. The purpose of this study was to evaluate the effect of chemotherapy on clinical outcome among patients with renal AL amyloidosis. PATIENTS AND METHODS: We evaluated factors influencing survival among 923 patients with renal AL amyloidosis observed during a 21-year period, including 221 patients who became dialysis dependent. Factors associated with renal outcome were analyzed, including serum free light chain (FLC) response to chemotherapy using a simple subtraction formula applicable to all stages of chronic kidney disease. Patient survival and graft survival were analyzed in 21 renal transplantation recipients. RESULTS: Median survival from diagnosis for the whole cohort was 35.2 months. Magnitude of FLC response with chemotherapy was strongly and independently associated with overall survival (P < .001) and renal outcome. Evaluable patients achieving more than 90% FLC response had a significantly higher rate of renal responses and lower rate of renal progression compared with patients achieving a 50% to 90% response, whose renal outcomes were, in turn, better than patients achieving less than 50% FLC response (P < .001). Median survival from dialysis dependence was 39.0 months, and median survival from renal transplantation was 89.0 months. CONCLUSION: Renal outcome and overall outcome in AL amyloidosis are strongly associated with FLC response to chemotherapy and are best among patients achieving more than 90% suppression of the amyloidogenic monoclonal component. Survival on dialysis was substantially superior to that previously reported, and renal transplantation should be considered in selected patients with AL amyloidosis with end-stage renal disease.
PURPOSE: Chemotherapy in AL (primary or light chain) amyloidosis is associated with improved survival, but its effect on renal outcome has not been examined systematically. The purpose of this study was to evaluate the effect of chemotherapy on clinical outcome among patients with renal AL amyloidosis. PATIENTS AND METHODS: We evaluated factors influencing survival among 923 patients with renal AL amyloidosis observed during a 21-year period, including 221 patients who became dialysis dependent. Factors associated with renal outcome were analyzed, including serum free light chain (FLC) response to chemotherapy using a simple subtraction formula applicable to all stages of chronic kidney disease. Patient survival and graft survival were analyzed in 21 renal transplantation recipients. RESULTS: Median survival from diagnosis for the whole cohort was 35.2 months. Magnitude of FLC response with chemotherapy was strongly and independently associated with overall survival (P < .001) and renal outcome. Evaluable patients achieving more than 90% FLC response had a significantly higher rate of renal responses and lower rate of renal progression compared with patients achieving a 50% to 90% response, whose renal outcomes were, in turn, better than patients achieving less than 50% FLC response (P < .001). Median survival from dialysis dependence was 39.0 months, and median survival from renal transplantation was 89.0 months. CONCLUSION: Renal outcome and overall outcome in AL amyloidosis are strongly associated with FLC response to chemotherapy and are best among patients achieving more than 90% suppression of the amyloidogenic monoclonal component. Survival on dialysis was substantially superior to that previously reported, and renal transplantation should be considered in selected patients with AL amyloidosis with end-stage renal disease.
Authors: A M Cornelison; R M Saliba; A Afrough; Y Dinh; Y Nieto; Q Bashir; N Shah; S Parmar; C Hosing; U Popat; E Shpall; R Champlin; M H Qazilbash Journal: Bone Marrow Transplant Date: 2015-10-19 Impact factor: 5.483
Authors: Kai Hu; Dan Liu; Peter Nordbeck; Maja Cikes; Stefan Störk; Bastian Kramer; Philipp Daniel Gaudron; Andreas Schneider; Stefan Knop; Georg Ertl; Bart Bijnens; Frank Weidemann; Sebastian Herrmann Journal: Int J Cardiovasc Imaging Date: 2015-07-16 Impact factor: 2.357
Authors: Jerry A Katzmann; Melissa R Snyder; S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; Joanne T Benson; Angela Dispenzieri Journal: Clin Chem Date: 2011-10-06 Impact factor: 8.327
Authors: C P Venner; J D Gillmore; S Sachchithanantham; S Mahmood; T Lane; D Foard; L Rannigan; S D J Gibbs; J H Pinney; C J Whelan; H J Lachmann; P N Hawkins; A D Wechalekar Journal: Leukemia Date: 2014-07-16 Impact factor: 11.528
Authors: Alfred Chung; Gregory P Kaufman; Surbhi Sidana; Erik Eckhert; Stanley L Schrier; Richard A Lafayette; Sally Arai; Ronald M Witteles; Michaela Liedtke Journal: Blood Adv Date: 2020-02-11
Authors: Rabya H Sayed; Ashutosh D Wechalekar; Janet A Gilbertson; Paul Bass; Shameem Mahmood; Sajitha Sachchithanantham; Marianna Fontana; Ketna Patel; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Julian D Gillmore Journal: Blood Date: 2015-09-21 Impact factor: 22.113